Brian Topp
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Pancreatic function and diabetes, Diabetes and associated disorders, Metabolism, Diabetes, and Cancer, Computational Drug Discovery Methods
Most-Cited Works
- → β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats(2001)373 cited
- → A Model of β -Cell Mass, Insulin, and Glucose Kinetics: Pathways to Diabetes(2000)325 cited
- → Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities(2019)87 cited
- → Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape(2018)74 cited
- → Metabolic adaptations to chronic glucose infusion in rats(2004)67 cited
- → Dynamics of insulin sensitivity, β-cell function, and β-cell mass during the development of diabetes in fa/fa rats(2007)56 cited
- → Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression(2023)39 cited
- → β‐cell deterioration – prospects for reversal or prevention(2001)28 cited
- → Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab(2021)26 cited
- → Treatment with Sitagliptin or Metformin Does Not Increase Body Weight despite Predicted Reductions in Urinary Glucose Excretion(2009)21 cited